Literature DB >> 30398152

Animal models of cholestasis: An update on inflammatory cholangiopathies.

Valeria Mariotti1, Massimiliano Cadamuro1, Carlo Spirli2, Romina Fiorotto2, Mario Strazzabosco2, Luca Fabris3.   

Abstract

Cholestasis is a frequent clinical condition initiating or complicating chronic liver diseases, particularly cholangiopathies, where the biliary epithelium is the primary target of the pathogenetic sequence. Until a few decades ago, understanding of cholestasis relied mostly on the experimental model of bile duct ligation in rodents. However, a simple model of biliary obstruction cannot reproduce the complex mechanisms and networks leading to cholestasis in cholangiopathies. These networks are underpinned by an intricate dysregulation of pro-inflammatory and pro-fibrotic signals involving besides cholangiocytes, multiple cell elements of both innate and adaptive immunity. Therefore, in the last years, a wide range of animal models of biliary injury have been developed, mostly in mice, following three main approaches, chemical induction, immunization and genetic manipulation. In this review, we will give an update of the animal models of the two main cholangiopathies, primary sclerosing cholangitis and primary biliary cholangitis, which have provided us with the most relevant insights into the pathogenesis of these still controversial diseases.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biliary fibrosis; Cholangiocyte; Ductular reaction; Primary biliary cholangitis; Primary sclerosing cholangitis

Mesh:

Year:  2018        PMID: 30398152     DOI: 10.1016/j.bbadis.2018.07.025

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  11 in total

1.  Knockout of the Tachykinin Receptor 1 in the Mdr2-/- (Abcb4-/-) Mouse Model of Primary Sclerosing Cholangitis Reduces Biliary Damage and Liver Fibrosis.

Authors:  Ludovica Ceci; Heather Francis; Tianhao Zhou; Thao Giang; Zhihong Yang; Fanyin Meng; Nan Wu; Lindsey Kennedy; Konstantina Kyritsi; Vik Meadows; Chaodong Wu; Suthat Liangpunsakul; Antonio Franchitto; Amelia Sybenga; Burcin Ekser; Romina Mancinelli; Paolo Onori; Eugenio Gaudio; Shannon Glaser; Gianfranco Alpini
Journal:  Am J Pathol       Date:  2020-07-23       Impact factor: 4.307

Review 2.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

Review 3.  Gut microbiota in non-alcoholic fatty liver disease and alcohol-related liver disease: Current concepts and perspectives.

Authors:  Juan P Arab; Marco Arrese; Vijay H Shah
Journal:  Hepatol Res       Date:  2020-01-13       Impact factor: 4.288

4.  Integrated Lipidomics and Metabolomics Study of Four Chemically Induced Mouse Models of Acute Intrahepatic Cholestasis.

Authors:  Weiwei Li; Hui Chen; Yihan Qian; Shouchuan Wang; Zichen Luo; Jinjun Shan; Xiaoni Kong; Yueqiu Gao
Journal:  Front Pharmacol       Date:  2022-06-08       Impact factor: 5.988

5.  Fermentable fibers induce rapid macro- and micronutrient depletion in Toll-like receptor 5-deficient mice.

Authors:  Rachel M Golonka; Beng San Yeoh; Yaqi Li; Piu Saha; Ahmed A Abokor; Xi Cheng; Xia Xiao; Darshan Shimoga Chandrashekar; Sooryanarayana Varambally; David J Gonzalez; A Catharine Ross; Matam Vijay-Kumar
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-03-23       Impact factor: 4.052

6.  BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination.

Authors:  Hyunkyung Jung; Jinjing Chen; Xiangming Hu; Hao Sun; Shwu-Yuan Wu; Cheng-Ming Chiang; Byron Kemper; Lin-Feng Chen; Jongsook Kim Kemper
Journal:  JCI Insight       Date:  2020-12-08

Review 7.  Rodent models of cholestatic liver disease: A practical guide for translational research.

Authors:  Eva Gijbels; Alanah Pieters; Kevin De Muynck; Mathieu Vinken; Lindsey Devisscher
Journal:  Liver Int       Date:  2021-02-23       Impact factor: 5.828

8.  ADAM Metalloproteinase Domain 17 Regulates Cholestasis-Associated Liver Injury and Sickness Behavior Development in Mice.

Authors:  Wagdi Almishri; Liam A Swain; Charlotte D'Mello; Tyson S Le; Stefan J Urbanski; Henry H Nguyen
Journal:  Front Immunol       Date:  2022-01-13       Impact factor: 7.561

Review 9.  Fibrotic Events in the Progression of Cholestatic Liver Disease.

Authors:  Hanghang Wu; Chaobo Chen; Siham Ziani; Leonard J Nelson; Matías A Ávila; Yulia A Nevzorova; Francisco Javier Cubero
Journal:  Cells       Date:  2021-05-05       Impact factor: 6.600

10.  Bile acid-activated macrophages promote biliary epithelial cell proliferation through integrin αvβ6 upregulation following liver injury.

Authors:  Adrien Guillot; Lucia Guerri; Dechun Feng; Seung-Jin Kim; Yeni Ait Ahmed; Janos Paloczi; Yong He; Kornel Schuebel; Shen Dai; Fengming Liu; Pal Pacher; Tatiana Kisseleva; Xuebin Qin; David Goldman; Frank Tacke; Bin Gao
Journal:  J Clin Invest       Date:  2021-05-03       Impact factor: 19.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.